Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications by Mario Sznol, Naiyer Rizvi

Get full text

714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metast... by Mario Sznol, Adil Daud, Scott M Turner, Chris N Barnes, Susan Owen, Eric A Lefebvre, Hardean E Achneck

21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients by Mario Sznol, Ruth Halaban, Yuval Shaked, Michal Harel, Coren Lahav, Eyal Jacob, Eran Issler, Haim Bar, Adam Dicker, Ofer Sharon, Antonietta Bacchiocchi

A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer. by Rossitza Lazova, Greggory S Laberge, Eric Duvall, Nicole Spoelstra, Vincent Klump, Mario Sznol, Dennis Cooper, Richard A Spritz, Joseph T Chang, John M Pawelek

Get full text

542 TIGIT as a potential therapeutic target in renal cell carcinoma by Mario Sznol, Harriet Kluger, Michael Hurwitz, Adebowale Adeniran, Peter Humphrey, David Braun, Lena Wirth, Soki Kashima, Hanna Soulati, Katrine Madsen, Katherine Sadak, Patrick Kenney

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors by Christian U. Blank, Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, Mario Sznol

Get full text

Immunotherapy utilization in stage IIIA melanoma: less may be more by Alexander E. Frey, Daniel M. Kerekes, Sajid A. Khan, Thuy T. Tran, Harriet M. Kluger, James E. Clune, Stephan Ariyan, Mario Sznol, Jeffrey J. Ishizuka, Kelly L. Olino

Get full text

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. by Ruth Halaban, Michael Krauthammer, Mattia Pelizzola, Elaine Cheng, Daniela Kovacs, Mario Sznol, Stephan Ariyan, Deepak Narayan, Antonella Bacchiocchi, Annette Molinaro, Yuval Kluger, Min Deng, Nam Tran, Wengeng Zhang, Mauro Picardo, Jan J Enghild

Get full text

Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerab... by Annika Belzer, BS, Jolanta Pach, BS, Ryland D. Mortlock, BS, James Clune, MD, Kelly Olino, MD, Mario Sznol, MD, Aarti Bhatia, MD, MPH, Barbara Burtness, MD, Sean Christensen, MD, PhD, Jonathan S. Leventhal, MD

Get full text

736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies by Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma by Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol, Charles Cha

Get full text

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study by Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz

Get full text

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma by Renee N Donahue, Jeffrey Schlom, James L Gulley, Mario Sznol, Andreas Schroeder, Julius Strauss, Luc Dirix, Michele Maio, Frank Beier, Alain Ravaud, Jean-Laurent Deville, Marco Maruzzo, XiaoZhe Wang, Yulia Vugmeyster, Sarah Chennoufi, Yo-Ting Tsai, Russell K Pachynski, Theodore S Gourdin, Joerg Seebeck

Get full text

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma by Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott

Get full text

Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis by Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune, Kelly Olino, Laxmi Parida, Joerg Nikolaus, Meiling Zhang, Shuang Zhao, Yan Wang, Gang Huang, Miaojian Wan, Xianan Li, Jian Cao, Qin Yan, Xiang Chen, Aaron M. Newman, Ruth Halaban

Get full text

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis by Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune, Kelly Olino, Laxmi Parida, Joerg Nikolaus, Meiling Zhang, Shuang Zhao, Yan Wang, Gang Huang, Miaojian Wan, Xianan Li, Jian Cao, Qin Yan, Xiang Chen, Aaron M. Newman, Ruth Halaban

Get full text

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better by Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu, Harriet M. Kluger

Get full text

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors by Mario Sznol, Michael Yellin, Tibor Keler, Jose Lutzky, Amy Weise, Margaret K Callahan, Osama Rahma, Rachel E Sanborn, Alexander Starodub, Deepa S Subramaniam, Antonio Jimeno, Tracey Rawls, David A Reardon, Daniel C Cho, Rhonda L Bitting, Michael J Pishvaian, Branimir I Sikic, Naiyer A Rizvi, Julie E Bauman, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Jeanny B Aragon-Ching, Thomas R Hawthorne

Get full text

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy by Meenu Sharma, Hiep Khong, Faisal Fa’ak, Salah-Eddine Bentebibel, Louise M. E. Janssen, Brent C. Chesson, Caitlin A. Creasy, Marie-Andrée Forget, Laura Maria S. Kahn, Barbara Pazdrak, Binisha Karki, Yared Hailemichael, Manisha Singh, Christina Vianden, Srinivas Vennam, Uddalak Bharadwaj, David J. Tweardy, Cara Haymaker, Chantale Bernatchez, Shixia Huang, Kimal Rajapakshe, Cristian Coarfa, Michael E. Hurwitz, Mario Sznol, Patrick Hwu, Ute Hoch, Murali Addepalli, Deborah H. Charych, Jonathan Zalevsky, Adi Diab, Willem W. Overwijk

Get full text